The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Open accessAbstract
The idea that conversion of glucose to ATP is an attractive target for cancer therapy has been supported in part by the observation that glucose deprivation induces apoptosis in rodent cells transduced with the proto-oncogene MYC, but not in the parental line. Here, we found that depletion of glucose killed normal human cells irrespective of induced MYC activity and by a mechanism different from apoptosis. However, depletion of glutamine, another major nutrient consumed by cancer cells, induced apoptosis depending on MYC activity. This apoptosis was preceded by depletion of the Krebs cycle intermediates, was prevented by two Krebs cycle substrates, but was unrelated to ATP synthesis or several other reported consequences of glutamine starvation. Our results suggest that the fate of normal human cells should be considered in evaluating nutrient deprivation as a strategy for cancer therapy, and that understanding how glutamine metabolism is linked to cell viability might provide new approaches for treatment of cancer.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In human cells, glucose deprivation killed normal fibroblasts independently of MYC and not by apoptosis, whereas glutamine deprivation induced MYC-dependent apoptosis. The glutamine-dependent death was linked to depletion of Krebs cycle intermediates and was prevented by pyruvate or oxaloacetate, but not by ATP, glutathione, DNA damage, protein synthesis, or mTOR mechanisms.
Key findings
- Glucose depletion killed IER-MYC human fibroblasts irrespective of ERTM-MYC activity; 0.5 mM glucose (2% of normal) killed more slowly but also independently of MYC. Death was not apoptosis, as shown by absence of chromatin condensation and failure of Bcl-2 to prevent death.
- Glutamine depletion killed IER-MYC cells faster when ERTM-MYC was active; IER control cells remained viable without glutamine regardless of OHT. Death was apoptosis via the intrinsic pathway: Bcl-2 and caspase-9 dominant-negative prevented death, while crmA had no effect.
- Apoptosis after glutamine depletion was not caused by ATP deficiency, glutathione deficiency, DNA damage, protein synthesis deficiency, mTOR inhibition, or cell cycle arrest. Glutamine deprivation depleted Krebs cycle intermediates except citrate and isocitrate; pyruvate or oxaloacetate completely prevented apoptosis but did not restore proliferation, and the NADH/NAD ratio remained unchanged.
- Nutrient requirements varied by cell type: HFF-ER-MYC reacted like IER-MYC; HA1E cells underwent apoptosis after glucose depletion and reacted to glutamine depletion like IER-MYC; RPE-hTERT cells survived without glutamine irrespective of ectopic MYC and died without glucose independently of MYC by a non-apoptotic mechanism.
Methods
- Normal human fibroblasts IMR90 were retrovirally transduced with ERTM-MYC (IER-MYC) or ERTM alone (IER); HFF, HA1E, and RPE-hTERT cells were also tested. ERTM-MYC was activated with 200 nM 4-hydroxytamoxifen (OHT), with ethanol as vehicle.
- Nutrient depletion used glucose-free or glutamine-free DMEM; standard concentrations were 10 mM glucose and 2 mM glutamine. Viability and apoptosis were assessed by annexin V/PI, Hoechst 33342 nuclear morphology, Trypan Blue, and immunoblotting/immunofluorescence.
- Metabolite and viability analyses included ATP by luciferin-luciferase, reduced glutathione by flow cytometry, NADH/NAD by enzymatic cycling, lactate by LDH reaction, and capillary electrophoresis coupled to mass spectrometry (CE-MS) for metabolite profiling. Results are presented as averages of independent experiments with SDs where indicated.
Limitations
- Stated: how abnormal MYC synergizes with glutamine depletion to induce apoptosis remains to be determined; the authors cannot exclude a combination of tested mechanisms or an unknown glutamine function. Mitochondrial NADH/NAD+ and FADH/FAD+ ratios were not measured.
- Stated: the effect of nutrient depletion varied across cell types, so conclusions may be difficult to extrapolate from one or a few experimental systems.
- Evident: the study relies on ectopically expressed inducible ERTM-MYC in cultured human cell lines rather than endogenous MYC or in vivo tumor models; several supporting observations are described as unpublished or are based on two independent experiments.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 18 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“depletion of glucose killed normal human cells irrespective of induced MYC activity and by a mechanism different from apoptosis.”
- Also stated in: § Glucose deprivation kills normal human fibroblasts not by apoptosis and largely independently of the MYC activity · plain
“depletion of glucose killed IER-MYC cells irrespective of ERTM-MYC activity (Fig. 1, A and B).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Glucose deprivation kills normal human fibroblasts not by apoptosis and largely independently of the MYC activity · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“by a mechanism different from apoptosis.”
- Also stated in: § Glucose deprivation kills normal human fibroblasts not by apoptosis and largely independently of the MYC activity · hedged
“cells in our system died by a process other than apoptosis, as indicated by the absence of characteristic chromatin condensation (Fig. 1 C) and the failure of Bcl-2, an inhibitor of apoptosis, to prevent cell death (Fig. 1 D).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Glucose deprivation kills normal human fibroblasts not by apoptosis and largely independently of the MYC activity · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“glutamine depletion even prevented the increase in p53 concentration caused by activation of ERTM-MYC”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > How does ectopic activity of MYC synergize with glutamine depletion to induce apoptosis?
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apoptosis was induced through the intrinsic pathway because Bcl-2 and a caspase-9 dominant-negative mutant (C9DN) prevented death (Fig. 3, A and B), whereas crmA, a viral inhibitor of the extrinsic pathway (Enari et al., 1995), had no effect (Fig. 3 D).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Glutamine deprivation induces apoptosis selectively in cells with acutely activated ER-MYC
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the antioxidants that we tested, tiron and N-acetyl-cysteine, failed to rescue the depleted cells from apoptosis (unpublished data)”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > How does glutamine depletion kill?
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“oxaloacetate, which is a membrane-permeable Krebs cycle intermediate, or pyruvate, which can enter the cycle by converting into acetyl-CoA or oxaloacetate, completely prevented apoptosis in the absence of glutamine (Fig. 8, A and B).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis caused by glutamine depletion is prevented by substrates of the Krebs cycle
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Oxaloacetate is a membrane-permeable Krebs cycle intermediate and pyruvate can enter the Krebs cycle by converting into acetyl-CoA or oxaloacetate.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BSO failed to induce apoptosis in IER-MYC cells (Fig. 6 C), suggesting that glutathione deficiency alone could not be the cause of apoptosis induced by glutamine depletion.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis is not caused by glutathione deficiency
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IER-MYC cells ceased to proliferate irrespective of ERTM-MYC activity if either any of the essential amino acids or glutamine were absent (unpublished data). Therefore, deregulation of cell cycle arrest by itself could not explain cell death caused by glutamine depletion.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > A cell cycle arrest is not the cause of apoptosis
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“omitting any of the essential amino acids from the tissue culture media failed to kill cells, at least over the time sufficient to kill by omitting glutamine (Fig. 4 B). Therefore, protein synthesis was not the cause of apoptosis induced by glutamine depletion.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > A deficiency in protein synthesis or inhibition of mTOR did not cause apoptosis induced by glutamine depletion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fig. S1 C demonstrates that the MYC moiety of ER-MYC makes cells sensitive to glutamine depletion”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Materials and methods > Online supplemental material
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 11
- Probably not a substantial claim. 15
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“glutamine depletion not only failed to increase the p53 concentration, but even reversed the increase induced by activation of ERTM-MYC (Fig. 7).”
- Also stated in: § Glutamine depletion does not cause DNA damage · plain
“Phosphorylation of H2AX, as detected by immunofluorescence, was induced by etoposide and by activation of ERTM-MYC, but not by glutamine depletion (Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200703099/DC1).”
- Also stated in: § Glutamine depletion does not cause DNA damage · hedged
“Hence, depletion of glutamine was unlikely to cause apoptosis by inducing DNA damage.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Glutamine depletion does not cause DNA damage
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Glutamine depletion does not cause DNA damage · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the NADH/NAD ratio remained unchanged (Fig. 8 D) and lactate was still produced (Fig. S3, available at http://www.jcb.org/cgi/content/full/jcb.200703099/DC1) after glutamine depletion, even though at a lower rate, indicating that pyruvate was unlikely to rescue from glutamine depletion by being a substrate of LDH.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis caused by glutamine depletion is prevented by substrates of the Krebs cycle
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“rapamycin caused S6 dephosphorylation but had no effect on cell viability over the time sufficient to kill cells by glutamine depletion (Fig. 4 C). Hence, glutamine depletion caused apoptosis by affecting pathways that did not require mTOR activity.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > A deficiency in protein synthesis or inhibition of mTOR did not cause apoptosis induced by glutamine depletion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in our hands depletion of essential amino acids caused cell cycle arrest but not apoptosis”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > How does ectopic activity of MYC synergize with glutamine depletion to induce apoptosis?
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fig. S3 documents that lactate production remains largely unchanged after depletion of glutamine and is independent of ER-MYC activity”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Materials and methods > Online supplemental material
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“glutamine depletion caused cell cycle arrest irrespective of the ERTM-MYC activity (unpublished data)”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > How does ectopic activity of MYC synergize with glutamine depletion to induce apoptosis?
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“we used IER-MYC that expressed C9DN (IER-MYC–C9DN), which prevents cell disassembly but not the preceding steps of apoptosis (Fearnhead et al., 1998), thus avoiding artifacts associated with cell decomposition.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis induced by glutamine depletion is not caused by ATP deficiency
What the sources say
- Not checked yetcites Fearnhead et al., 1998
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Identification was based on retention time and exact mass measurements after alignment of both axes with reference compounds, and confirmed by spiked standards.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Materials and methods > CE-MS analysis
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“metabolism of human cells is changed by oncogenes in various ways (Ramanathan et al., 2005)”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Modification of nutrient requirements by acute activation of ectopically expressed MYC vary with cell type
What the sources say
- Not checked yetcites Ramanathan et al., 2005
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“previous reports suggested that depletion of glutamine kills because of stress caused by deficiency in proteins, ATP, glutathione, or nucleotides (for review see Ahluwalia et al., 1990; Fuchs and Bode, 2006).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Glutamine deprivation induces apoptosis selectively in cells with acutely activated ER-MYC
What the sources say
- Not checked yetcites Ahluwalia et al., 1990
- Not checked yetcites Fuchs and Bode, 2006
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true.
None of the sources cited for this claim have been checked yet.
In the paper
“Adding OHT to the tissue culture medium caused translocation of ERTM-MYC to the nucleus (Fig. S1 A, available at http://www.jcb.org/cgi/content/full/jcb.200703099/DC1) and increased sensitivity of the cells to DNA damage (Fig. S1 B), which confirmed that the system functioned as expected (Eilers et al., 1989; Littlewood et al., 1995).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results
What the sources say
- Not checked yetcites Eilers et al., 1989
- Not checked yetcites Littlewood et al., 1995
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Pyruvate might affect cell viability by being a substrate of lactate dehydrogenase (LDH), which oxidizes NADH to NAD (Zielke et al., 1980).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis caused by glutamine depletion is prevented by substrates of the Krebs cycle
What the sources say
- Not checked yetcites Zielke et al., 1980
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Treatments that induce glutamine deficiency or interfere with its metabolism as a substrate for nucleotide synthesis were highly successful in animals, but turned out to be unacceptably toxic in people and were largely abandoned (Ahluwalia et al., 1990).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > Relevance of glutamine metabolism to cancer therapy
What the sources say
- Not checked yetcites Ahluwalia et al., 1990
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, our study is consistent with the view that metabolic changes associated with carcinogenesis, and the energy metabolism in particular, might be much more complex than Warburg postulated”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > Relevance of glutamine metabolism to cancer therapy
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“our observations indicated that glutamine in our system is either the main source of Krebs cycle intermediates, as in some proliferating normal and cancer cells (Reitzer et al., 1979; Moreadith and Lehninger, 1984; Zielke et al., 1984; Kovacevic et al., 1991; Baggetto, 1992; Petch and Butler, 1994), or regulates the Krebs cycle activity.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > How does glutamine depletion kill?
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggests that the potential of glutamine metabolism as a target for cancer therapy may need revisiting”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion > Relevance of glutamine metabolism to cancer therapy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
In the paper
“the NADH/NAD ratio determines rates of many processes, from glycolysis to histone modifications (for review see Ladurner, 2006)”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis caused by glutamine depletion is prevented by substrates of the Krebs cycle
What the sources say
- Not checked yetcites Ladurner, 2006
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“capillary electrophoresis coupled to mass spectrometry (CE-MS), an approach that estimates concentration of multiple metabolites in one sample (Soga et al., 2003).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis caused by glutamine depletion is prevented by substrates of the Krebs cycle
What the sources say
- Not checked yetcites Soga et al., 2003
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All changes in brightness or contrast, if any done, were applied to the entire image.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Materials and methods > Immunofluorescence
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To further decrease the chances of clonal selection, we used retroviral transduction rather than transient transfection to generate populations of normal human fibroblasts IMR90 that expressed ERTM-MYC (IER-MYC) or ERTM (IER); the latter served to exclude effects of OHT unrelated to MYC activity.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“our results demonstrated that dependence of cells on glucose and the effects of its depletion vary among cell types and can depend on the combination of oncogenes expressed in these cells.”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the Krebs cycle is not only a source of NADH for oxidative phosphorylation, but also a “hub” of numerous metabolic pathways (http://www.tcd.ie/Biochemistry/IUBMB-Nicholson/minimaps.html)”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Results > Apoptosis caused by glutamine depletion is prevented by substrates of the Krebs cycle
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results suggest that the fate of normal human cells should be considered in evaluating nutrient deprivation as a strategy for cancer therapy”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Abstract
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
None of the sources cited for this claim have been checked yet.
In the paper
“depletion of glucose induced apoptosis in rodent cells that were transduced with MYC, an oncogene that is abnormally expressed in many human cancers (Nesbit et al., 1999), but not in the parental cell line (Shim et al., 1998).”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Introduction
What the sources say
- Not checked yetcites Shim et al., 1998
- Not checked yetcites Nesbit et al., 1999
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Fig. S1, A and B document that ER-MYC is activated as expected”
§ Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells > Materials and methods > Online supplemental material
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
Metabolism can vary among species.
“Considering that metabolism can vary among species, and that human rather than animal tumors are of primary interest, we used human cells.”
The paper relies on this without support.
Glutamine is made by cells, making the requirement for exogenous glutamine appear unnecessary.
“However, glutamine is made by cells, which makes the requirement for exogenous glutamine appear unnecessary.”
The paper relies on this without support.
Oxaloacetate is a membrane-permeable Krebs cycle intermediate and pyruvate can enter the Krebs cycle by converting into acetyl-CoA or oxaloacetate.
“oxaloacetate, which is a membrane-permeable Krebs cycle intermediate, or pyruvate, which can enter the cycle by converting into acetyl-CoA or oxaloacetate, completely prevented apoptosis in the absence of glutamine (Fig. 8, A and B).”
The paper relies on this without support.
Why glutamine is required for cell viability is not entirely clear.
“Surprisingly, why glutamine is required for cell viability, or, in other words, why depletion of glutamine would kill cells, is not entirely clear.”
The paper relies on this without support.
p53 is mutated in many cancers.
“which is an advantage as this protein is mutated in many cancers”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, depending on the tissue of origin, cancer cells use various routes of glutamine metabolism. Some have been shown to require an exogenous glutamine supply for malignant proliferation [71,72], whereas others do not [73] and can synthesize it de novo [74].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cancer cells often consume glutamine, and those dependent on Myc signaling are highly sensitive to glutamine withdrawal (Yuneva et al., 2007).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Yuneva et al., 2007
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, checkpoint kinase 1 (CHK1) inhibitors625–627 and glutaminase (GLS) inhibitors628–634 are also considered potential candidates for treating Myc-overexpressing cancers.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [628]
In the citing paper
“Providing cells with αKG, oxaloacetate, or pyruvate is sufficient to rescue cancer cell proliferation in conditions of glutamine starvation, confirming that glutamine supports proliferation by replenishing depleted TCA cycle intermediates, a process termed anaplerosis (Altman et al., 2016; Weinberg et al., 2010; Yuneva et al., 2007).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2007
In the citing paper
“In certain contexts, MYC-transformed cancers become glutamine dependent and undergo apoptosis in the absence of glutamine (Yuneva et al., 2007).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2007
In the citing paper
“In c-myc-transformed cells in particular, glutamine deprivation leads to the collapse of the TCA cycle and triggers cell death, which can be rescued by the addition of oxaloacetate or a membrane-permeable form of α-ketoglutarate (Wise et al., 2008; Yuneva et al., 2007).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Yuneva et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
MYC-associated DNA damage is both reported and denied
MajorThe Discussion says no increase in DNA damage was detected after ERTM-MYC activation, but the Results say ERTM-MYC activation induced phosphorylation of H2AX, which the paper uses as a DNA-damage reporter.
“However, we detected no increase in the concentration of ROS or DNA damage either after activation of ERTM-MYC or depleting glutathione.”
“Phosphorylation of H2AX, as detected by immunofluorescence, was induced by etoposide and by activation of ERTM-MYC, but not by glutamine depletion (Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200703099/DC1).”
CrmA result cites a nonexistent Figure 3 panel
MinorThe text cites Figure 3 D for the CrmA result, but the Figure 3 caption identifies the CrmA experiment as panel C and lists no panel D.
“whereas crmA, a viral inhibitor of the extrinsic pathway (Enari et al., 1995), had no effect (Fig. 3 D).”
“(C) IER-MYC transduced with CrmA or vector alone were treated as in A except anti-Fas (α-CD95) antibody was added as indicated.”
Figure 6 C refers to a schematic as its treatment protocol
MinorThe caption says the cells in panel C were treated as in panel A, but panel A is a biosynthesis diagram. The treatment conditions are described in panel B.
“(C) IER-MYC cells were treated as in A except the cells were collected at 24 h of incubation in the indicated media to determine the rate of apoptosis.”
“(A) Biosynthesis of glutathione. (B) IER-MYC–C9DN were incubated with OHT (MYCON) or ethanol (MYCOFF) for 24 h, and then transferred to the medium depleted of glutamine or supplemented with 100 μM BSO.”
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 20,078
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Glucose metabolism has drawn much of the attention (for review see Garber, 2006) from the time when Otto Warburg found that some cancer cells consume more glucose than normal cells and proposed that a failure to make ATP by oxidative phosphorylation is the cause of cancer (Warburg, 1956).”
BackgroundDNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5858 · Cited by 5,438 · cited 4×
“S2 visualizes localization of phosphorylated histone H2AX in cells deprived of glutamine or treated with etoposide.”
BackgroundInfluentialCillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,487 · cited 1×
“For example, citrate is used for the synthesis of fatty acids whose defi ciency might change permeability of mitochondrial membranes and affect their regulation by the Bcl-2 proteins (Green and Kroemer, 2004).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 1×
“Some of the Krebs cycle intermediates, such as fumarate, succinate, and 2-oxoglutarate, can function as messenger and cofactor molecules directly regulating activity of enzymes and thereby contributing to regulation of gene transcription and/or tumorigenesis (Selak et al., 2005; Chen et al., 2006).”
BackgroundRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“The differences between cancer and normal cells in consumption and metabolism of basic nutrients have been considered a promising cancer therapy target for several decades (for review see Thompson et al., 2005; Shaw and Cantley, 2006).”
BackgroundGriffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683
Translational control in stress and apoptosis
Holčı́k, M., & Sonenberg, N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1618 · Cited by 1,409 · cited 1×
“…review see Baggetto, 1992; Curi et al., 2005), abnormal expression of MYC accelerates cell proliferation and changes metabolism of mitochondria (Morrish et al., 2003; Li et al., 2005), and even a transient decrease in ATP concentration can cause apoptosis (Izyumov et al., 2004; Shaw et al., 2004).”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“The availability of nitrogen sources, and glutamine in particular, regulates the activity of mTOR, a kinase that controls protein synthesis, cell proliferation, and other processes that require nitrogen (for review see Sabatini, 2006).”
Background
Flagged first, then by citations
Research works printed but not linked: 6
- 1969, Cancer Res., 29, 669
- 1969, Cancer Res., 29, 1195
- 1985, Eur. J. Cell Biol., 36, 176
- 2004, Anticancer Res., 24, 1121
- 2003, Cancer Res., 63, 7330
- 1984, Fed. Proc., 43, 121
Cited by
Sorted by citations
Items 401–500 of 692
Intersections between mitochondrial sirtuin signaling and tumor cell metabolism
Herrera, K. N. G., Lee, J. J., & Haigis, M. C. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1031879 · Cited by 25
c-MYC responds to glucose deprivation in a cell-type-dependent manner
Wu, S., Yin, X., Fang, X., Zheng, J., Li, L., Liu, X., & Chu, L. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.57 · Cited by 23
Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma
Dong, M., Miao, L., Zhang, F., Sheng-shui, L., Han, J., Yu, R., & Qie, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s167408 · Cited by 22
Yeo, H. C., Park, S., Tan, T. R. M., Ng, S. K., Lakshmanan, M., & Lee, D. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28104 · Cited by 21
Pharmacologic approaches to amino acid depletion for cancer therapy
Wilder, C. S., Chen, Z., & DiGiovanni, J. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23349 · Cited by 23
Bonanomi, M., Salmistraro, N., Fiscon, G., Conte, F., Paci, P., Bravatà, V., Forte, G. I., Volpari, T., Scorza, M., Mastroianni, F., et al. (2021) · Cancers · doi:10.3390/cancers13205058 · Cited by 23
Sun, L., Yi, L., Zhang, C., et al. (2016) · Journal of General Virology · doi:10.1099/jgv.0.000597 · Cited by 23
Carlessi, R., Rowlands, J., Ellison, G., de Oliveira, H. H., Newsholme, P., & Mamotte, C. D. S. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.04.013 · Cited by 23
Targeting Cancer Metabolism and Current Anti-Cancer Drugs
Sukjoi, W., Ngamkham, J., Attwood, P. V., & Jitrapakdee, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_2 · Cited by 23
Shrotriya, S., Deep, G., Lopert, P., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22246 · Cited by 23
Graves, J. A., Rothermund, K. D., Wang, T., Qian, W., Houten, B. V., & Prochownik, E. V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013717 · Cited by 23
Glioma Stem-Like Cells and Metabolism: Potential for Novel Therapeutic Strategies
Harland, A. J., Liu, X., Ghirardello, M., Galán, M. C., Perks, C. M., & Kurian, K. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743814 · Cited by 21
Valter, K., Chen, L., Kruspig, B., Maximchik, P. V., Cui, H., Zhivotovsky, B., & Gogvadze, V. G. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.016 · Cited by 22
The Xenopus oocyte: A model for studying the metabolic regulation of cancer cell death
Nutt, L. K. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.03.015 · Cited by 24
Marín‐Aguilera, M., Pereira, M. V., Jiménez, N., Reig, Ò., Cuartero-Gorjón, A., Victoria, I., Aversa, C., Ferrer‐Mileo, L., Prat, A., & Mellado, B. (2021) · Cancers · doi:10.3390/cancers13194960 · Cited by 19
Zhang, J., Chen, M., Yang, Y., Liu, Z., Guo, W., Xiang, P., Zeng, Z., Wang, D., & Xiong, W. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31349 · Cited by 23
Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
Banerji, V., & Gibson, S. B. (2012) · International Journal of Cell Biology · doi:10.1155/2012/595976 · Cited by 20
Li, Y., Yuan, W., Gao, J., Fan, C., Wu, W., & Bai, F. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2017.06.008 · Cited by 20
Köksal, G. M., Erbabacan, E., Tunalı, Y., et al. (2014) · PubMed · doi:10.6133/apjcn.2014.23.1.11 · Cited by 21
Zhao, C., Zhang, H., Zhou, J., Lü, Q., Zhang, Y., Yu, X., Wang, S., Liu, R., Pu, Y., & Yin, L. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111997 · Cited by 23
Al-Zebeeby, A., Vogler, M., Milani, M., Richards, C., Alotibi, A., Greaves, G., Dyer, M. J. S., Cohen, G. M., & Varadarajan, S. (2018) · Haematologica · doi:10.3324/haematol.2018.204701 · Cited by 22
Zanchetta, L. M., Garcia, A., Lyng, F. M., Walsh, J., & Murphy, J. E. J. (2011) · International Journal of Radiation Biology · doi:10.3109/09553002.2011.556175 · Cited by 21
The metabolic switch and its regulation in cancer cells
Zhou, S., Huang, C., & Wei, Y. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-4041-1 · Cited by 21
Powell, J. D., Hutchison, J. R., Hess, B., et al. (2015) · Journal of Applied Microbiology · doi:10.1111/jam.12872 · Cited by 21
Dietary approaches for exploiting metabolic vulnerabilities in cancer
Menyhárt, O., & Győrffy, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189062 · Cited by 23
The metabolic underpinnings of sebaceous lipogenesis
Schmidt, M., Binder, H., & Schneider, M. R. (2025) · Communications Biology · doi:10.1038/s42003-025-08105-9 · Cited by 24
Myc requires RhoA/SRF to reprogram glutamine metabolism
Haikala, H. M., Marques, E., Turunen, M. M., & Klefström, J. T. (2016) · Small GTPases · doi:10.1080/21541248.2016.1224287 · Cited by 21
Importance of lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs) in cancer cells
Hatami, H., Sajedi, A., Mir, S. M., & Memar, M. Y. (2022) · Health Science Reports · doi:10.1002/hsr2.996 · Cited by 21
Burzynski, S. R., & Patil, S. (2014) · Journal of Cancer Therapy · doi:10.4236/jct.2014.510099 · Cited by 20
Targeting metabolic abnormalities to reverse fibrosis in iatrogenic laryngotracheal stenosis
Murphy, M. K., Motz, K., Ding, D., Yin, L. X., Duvvuri, M., Feeley, M., & Hillel, A. T. (2017) · The Laryngoscope · doi:10.1002/lary.26893 · Cited by 20
Yu, Y., Clippinger, A. J., Pierciey, F. J., & Alwine, J. C. (2011) · Advances in virus research · doi:10.1016/b978-0-12-385987-7.00003-8 · Cited by 20
Effect of Glutamine Enriched Nutrition Support on Surgical Patients with Gastrointestinal Tumor
Kang, K., Xiao-liang, S., Zhang, Y., Liu, X.-L., & Zhao, J. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.149219 · Cited by 20
NUDT21 suppresses the growth of small cell lung cancer by modulating GLS1 splicing
Gao, C., Xu, Q., Xiao, F., Wang, H., Wu, C.-T., & Wang, L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.089 · Cited by 18
In vivo analysis of lung cancer metabolism: nothing like the real thing
Hensley, C. T., & DeBerardinis, R. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79188 · Cited by 19
NMR-based Metabolomics Analysis of Liver from C57BL/6 Mouse Exposed to Ionizing Radiation
Xiao, X., Hu, M. Y., Zhang, X., & Hu, J. Z. (2017) · Radiation Research · doi:10.1667/rr14602.1 · Cited by 18
Asparagine bioavailability regulates the translation of MYC oncogene
Srivastava, S., Jiang, J., Misra, J., Seim, G. L., Staschke, K. A., Zhong, M., Zhou, L., Liu, Y., Chen, C., Davé, U. P., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02474-9 · Cited by 20
Avramis, V. I. (2011) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31823313be · Cited by 19
Belapurkar, R., Pfisterer, M., Dreute, J., Werner, S., Zukunft, S., Fleming, I., Kracht, M., & Schmitz, M. L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06012-7 · Cited by 21
Dragan, M., Nguyen, M.-U., Guzman, S., Goertzen, C., Brackstone, M., Dhillo, W. S., Bech, P., Clarke, S. A., Abbara, A., Tuck, A. B., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2305-7 · Cited by 19
Glutamine deprivation sensitizes human breast cancer MDA-MB-231 cells to TRIAL-mediated apoptosis
Dilshara, M. G., Jeong, J.-W., Jayasooriya, R. G. P. T., Molagoda, I. M. N., Lee, S., Park, S. R., Choi, Y. H., & Kim, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.059 · Cited by 18
Perciavalle, R. M. (2012) · doi:10.21007/etd.cghs.2012.0242 · Cited by 17
Li, Y., Gao, J., Pei, X., Du, C., Fan, C., Yuan, W., & Bai, F. (2019) · Microbial Cell Factories · doi:10.1186/s12934-019-1077-1 · Cited by 17
Chagovets, V., Starodubtseva, N. L., Tokareva, A., Novoselova, A., Patysheva, M. R., Larionova, I., Prostakishina, E. A., Rakina, M. A., Казакова, А., Topolnitskiy, E. B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332043 · Cited by 19
Ježek, J., Plecitá‐Hlavatá, L., & Ježek, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00637 · Cited by 20
1H-NMR-Based Metabolomic Analysis of Cerebrospinal Fluid From Adult Bilateral Moyamoya Disease
Jeon, J. P., Yun, T., Jin, X., et al. (2015) · Medicine · doi:10.1097/md.0000000000000629 · Cited by 18
Fazzari, J., Linher‐Melville, K., & Singh, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160509123042 · Cited by 16
Metabolic Diversity in Human Non-Small Cell Lung Cancer CellsPreprint
Chen, P.-H., Cai, L., Huffman, K. E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/561688 · Cited by 18
Cellular response to glutamine and/or glucose deprivation in in�vitro transformed human fibroblasts
Chiodi, I., Picco, G., Martino, C., & Mondello, C. (2019) · Oncology Reports · doi:10.3892/or.2019.7125 · Cited by 18
Mitochondrial dynamics and metabolism in induced pluripotency
Prieto, J., Ponsoda, X., Belmonte, J. C. I., & Torres, J. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110870 · Cited by 18
Ismail, A. M., In, L. L. A., Tasyriq, M., Syamsir, D. R., Awang, K., Mustafa, A. H. O., Idris, O. F., Fadl-Elmula, I. M., & Hasima, N. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.10.024 · Cited by 17
Liao, P., Chang, N., Xu, B., Qiu, Y., Wang, S., Zhou, L., He, Y., Xie, X., & Li, Y. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12557 · Cited by 16
Metabolic effects of anti-angiogenic therapy in tumors
Zulato, E., Curtarello, M., Nardo, G., & Indraccolo, S. (2012) · Biochimie · doi:10.1016/j.biochi.2012.01.001 · Cited by 17
Peng, J., Li, X., Huang, M., Ma, M., Huang, Q., Huang, N., & Cheng, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117764 · Cited by 18
GLS and GLS2 Glutaminase Isoenzymes in the Antioxidant System of Cancer Cells
Santos-Jiménez, J. D. L., Campos-Sandoval, J. A., Alonso, F. J., Márquez, J., & Matés, J. M. (2024) · Antioxidants · doi:10.3390/antiox13060745 · Cited by 25
Jiao, Y., JI, L., Kuang, Y., & Yang, Q. (2017) · Neoplasma · doi:10.4149/neo_2017_204 · Cited by 16
Moon, D., Hauck, J. S., Jiang, X., Quang, H., Xu, L., Zhang, F., Gao, X., Wild, R., Everitt, J. I., Macias, E., et al. (2023) · The Prostate · doi:10.1002/pros.24654 · Cited by 15
GlutaMAX prolongs the shelf life of the culture medium for porcine parthenotes
Zhao, M., Kim, N., & Cui, X. (2015) · Theriogenology · doi:10.1016/j.theriogenology.2015.08.014 · Cited by 16
Metabolic pathways in cancers: key targets and implications in cancer therapy
Vijayakumar, S. N., Sethuraman, S., & Krishnan, U. M. (2015) · RSC Advances · doi:10.1039/c5ra06505d · Cited by 16
Jung, K., Lee, J., Park, J., Moon, S. H., Cho, Y., & Lee, K. (2019) · Oncology Reports · doi:10.3892/or.2019.7436 · Cited by 16
Liao, G.-Y., Lee, M., Fan, J.-J., Hsiao, P., Lee, C.-S., Su, S.-Y., Hwang, J.-J., & Ke, F. (2019) · Biology Open · doi:10.1242/bio.038257 · Cited by 18
Krajčová, A., Žiak, J., Jiroutková, K., Pátková, J., Elkalaf, M., Džupa, V., Trnka, J., & Duška, F. (2013) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607113513801 · Cited by 14
Right on TARGET: glutamine metabolism in cancer
Ratnikov, B. I., Jeon, Y. J., Smith, J. W., & Ronai, Z. A. (2015) · Oncoscience · doi:10.18632/oncoscience.205 · Cited by 15
Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis
Lee, E. J., Duggirala, K. B., Lee, Y., Yun, M. R., Jang, J., Cyriac, R., Jung, M. E., Choi, G., Chae, C. H., Cho, B. C., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128956 · Cited by 19
Mitochondrial substrates in cancer: Drivers or passengers?
Kruspig, B., Zhivotovsky, B., & Gogvadze, V. G. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.08.007 · Cited by 15
Cellular energetics as a target for tumor cell elimination
Maximchik, P. V., Kulikov, A. V., Zhivotovsky, B., & Gogvadze, V. G. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020012 · Cited by 16
Ohba, S., & Hirose, Y. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03351-4 · Cited by 14
The Enchytraeus crypticus stress metabolome – CuO NM case study
Maria, V. L., Licha, D., Ranninger, C., et al. (2018) · Nanotoxicology · doi:10.1080/17435390.2018.1481237 · Cited by 14
Guo, Z., Ma, J., Zhang, J.-Q., Yan, L., Zhou, Y., Mao, X., Li, S.-W., & Zhou, X.-B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524801 · Cited by 17
Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells
Steifensand, F., Gallwas, J. K. S., Bauerschmitz, G. J., & Gründker, C. (2021) · Cells · doi:10.3390/cells10092398 · Cited by 15
Proteomics and metabolomics in cancer drug development
D’Alessandro, A., & Zolla, L. (2013) · Expert Review of Proteomics · doi:10.1586/14789450.2013.840440 · Cited by 14
Yegambaram, M., Sun, X., Lü, Q., Flores, A. G., Zemskova, M., Soto, J. E., Rauckhorst, A. J., Maltepe, E., Wang, T., Fineman, J. R., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103765 · Cited by 17
Bernhardt, S., Tönsing, C., Mitra, D., Erdem, N., Müller‐Decker, K., Korf, U., Kreutz, C., Timmer, J., & Wiemann, S. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00944 · Cited by 13
Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia
Chihanga, T., Vicente-Muñoz, S., Ruiz-Torres, S., Pal, B., Sertorio, M. G., Andreassen, P. R., Khoury, R. A., Mehta, P. A., Davies, S. M., Lane, A. N., et al. (2022) · Cancers · doi:10.3390/cancers14082040 · Cited by 12
Assi, G., & Faour, W. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175830 · Cited by 13
Nutrient deprivation in neuroblastoma cells alters 4-hydroxynonenal-induced stress response
Zimmermann, L., Moldzio, R., Vazdar, K., Krewenka, C., & Pohl, E. E. (2016) · Oncotarget · doi:10.18632/oncotarget.14132 · Cited by 12
Gaglio, D., Valtorta, S., Ripamonti, M., Bonanomi, M., Damiani, C., Todde, S., Negri, A. S., Sanvito, F., Mastroianni, F., Campli, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10470 · Cited by 15
Prasad, A., Roy, A. C., Priya, K., Meena, R., & Ghosh, I. (2023) · 3 Biotech · doi:10.1007/s13205-023-03759-w · Cited by 14
Khan, M. W., Layden, B. T., & Chakrabarti, P. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.013 · Cited by 13
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
D’Avola, A., Kľučková, K., Finch, A. J., & Riches, J. C. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s366627 · Cited by 13
Spatial metabolomics in head and neck tumors: a review
Zheng, Y., Chen, L., Chu, Y., Gu, S., Deng, H., & Shen, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1213273 · Cited by 13
Pandian, S. R. K., Deepak, V., Hariharan, N., & Sundar, K. (2014) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-014-9840-4 · Cited by 13
Rezinciuc, S., Bezavada, L., Bahadoran, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.14.906826 · Cited by 12
An Update on the Metabolic Landscape of Oncogenic Viruses
Gaballah, A. H., & Bartosch, B. (2022) · Cancers · doi:10.3390/cancers14235742 · Cited by 13
Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity
Starková, J., Heřmanová, I., Hložková, K., Hararova, A., & Trka, J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.012 · Cited by 13
Liu, H., Feng, Y., Yang, M., Huang, Y., Li, M., Geng, Y., Ouyang, P., Chen, D., Yang, S., Yin, L., et al. (2023) · BMC Genomics · doi:10.1186/s12864-023-09620-x · Cited by 12
Recent advances in nanomedicine for metabolism-targeted cancer therapy
Da, J., Di, X., Xie, Y., Li, J., Zhang, L., & Liu, Y. (2024) · Chemical Communications · doi:10.1039/d3cc05858a · Cited by 12
Glutamine Addiction of Cancer Cells
Desideri, E., & Ciriolo, M. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1932-1_8 · Cited by 11
Intertwined regulation between RNA m6A modification and cancer metabolism
Liu, J., Huang, H., Zhang, M., Qing, G., & Liu, H. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100075 · Cited by 15
Karabulutoglu, M., Finnon, R., Imaoka, T., Friedl, A. A., & Badie, C. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1490042 · Cited by 11
Canceromics Studies Unravel Tumor’s Glutamine Addiction After Metabolic Reprogramming
Márquez, J., Matés, J. M., Alonso, F. J., Martín‐Rufián, M., Lobo, C., & Campos-Sandoval, J. A. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_12 · Cited by 11
Vadlakonda, L., Indracanti, M., Kalangi, S. K., Gayatri, B. M., Gajula, N. N., & Reddy, A. B. M. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00566-5 · Cited by 11
Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy
Masci, D., Puxeddu, M., Silvestri, R., & Regina, G. L. (2024) · Molecules · doi:10.3390/molecules29092110 · Cited by 11
Enzymatic depletion of circulating glutamine is immunosuppressive in cancers
Kumar, M., Leekha, A., Nandy, S., Kulkarni, R. S., Martinez-Paniagua, M. A., Sefat, K. M. S. R., Willson, R. C., & Varadarajan, N. (2024) · iScience · doi:10.1016/j.isci.2024.109817 · Cited by 10
Li, J., Li, X., Wang, S., Zhang, Y., Zhao, S., Zhang, D., Meng, X., Zhang, Y., & Lin, J. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240069 · Cited by 12
Application of metabolomics in oral squamous cell carcinoma
Luo, G., Wang, S., Lu, W., Ju, W., Li, J., Tan, X. Y., Zhao, H., Han, W., & Yang, X. (2024) · Oral Diseases · doi:10.1111/odi.14895 · Cited by 11
Fang, C., Zou, C., Fu, Y., Li, J., Li, Y., Ma, Y., Zhao, S., & Li, C. (2018) · Epigenomics · doi:10.2217/epi-2017-0071 · Cited by 9
Blaylock, R. L. (2019) · Surgical Neurology International · doi:10.25259/sni_361_2019 · Cited by 10
Growth Signaling Networks Orchestrate Cancer Metabolic NetworksPreprint
Manning, B. D., & Dibble, C. C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041543 · Cited by 11
Freidman, N., Briot, C., & Ryan, R. M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102178 · Cited by 10
Metadata
- Authors
- Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y.
- Affiliations
- University of California, San Francisco (US)
- ETH Zurich (CH)
- University of Regensburg (DE)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Lazebnik, Yuri
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2007-07-02
- Volume
- 178
- Issue
- 1
- Pages
- 93-105
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2064426
- OpenAlex
- W2112861594
- Cited by
- 690
- References
- 72
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 26 · 2023: 46 · 2022: 36 · 2021: 36 · 2020: 32 · 2019: 40 · 2018: 39 · 2017: 56 · 2016: 49 · 2015: 47 · 2014: 50 · 2013: 46 · 2012: 42
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- National Cancer Institute (CA-13106-31, P01CA013106)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- glutamine deprivation, glucose deprivation, c-Myc, apoptosis, Krebs cycle intermediates, nutrient deprivation, cancer therapy, glutamine metabolism, cell viability, glucose metabolism
- MeSH terms
- Proto-Oncogene Mas, Cell Line, Cells, Cultured, Fibroblasts, Gene Expression Regulation, Glucose, Glutamine, Humans, Lung, Male, Retroviridae, Skin, Transduction, Genetic, Proto-Oncogene Proteins c-myc, Apoptosis, Cell Culture Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
